Phio Pharmaceuticals Files 8-K on Financials
Ticker: PHIO · Form: 8-K · Filed: Apr 2, 2024 · CIK: 1533040
| Field | Detail |
|---|---|
| Company | Phio Pharmaceuticals Corp. (PHIO) |
| Form Type | 8-K |
| Filed Date | Apr 2, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-K
TL;DR
Phio Pharma dropped an 8-K on April 2nd detailing their financials. Check it out.
AI Summary
Phio Pharmaceuticals Corp. filed an 8-K on April 2, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located in Marlborough, Massachusetts.
Why It Matters
This 8-K filing provides an update on Phio Pharmaceuticals' financial status and operational results, which is crucial information for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial information and does not appear to contain any significant new risks or material adverse events.
Key Players & Entities
- Phio Pharmaceuticals Corp. (company) — Registrant
- April 2, 2024 (date) — Date of earliest event reported
- Marlborough, Massachusetts (location) — Address of principal executive offices
- 001-36304 (other) — Commission File Number
- RXi Pharmaceuticals Corp (company) — Former company name
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Phio Pharmaceuticals Corp.'s results of operations and financial condition, and to include financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on April 2, 2024.
Where are Phio Pharmaceuticals Corp.'s principal executive offices located?
Phio Pharmaceuticals Corp.'s principal executive offices are located at 11 Apex Drive, Suite 300A, PMB 2006, Marlborough, Massachusetts 01752.
What was Phio Pharmaceuticals Corp. formerly known as?
Phio Pharmaceuticals Corp. was formerly known as RXi Pharmaceuticals Corp.
What is the Commission File Number for Phio Pharmaceuticals Corp.?
The Commission File Number for Phio Pharmaceuticals Corp. is 001-36304.
Filing Stats: 514 words · 2 min read · ~2 pages · Grade level 9.8 · Accepted 2024-04-02 07:30:12
Key Financial Figures
- $0.0001 — h registered: Common Stock, par value $0.0001 per share PHIO The Nasdaq Capital M
Filing Documents
- phio_8k.htm (8-K) — 27KB
- phio_ex9901.htm (EX-99.1) — 39KB
- image_001.jpg (GRAPHIC) — 2KB
- 0001683168-24-002050.txt ( ) — 246KB
- phio-20240402.xsd (EX-101.SCH) — 3KB
- phio-20240402_lab.xml (EX-101.LAB) — 33KB
- phio-20240402_pre.xml (EX-101.PRE) — 22KB
- phio_8k_htm.xml (XML) — 4KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On April 2, 2024, Phio Pharmaceuticals Corp. (the "Company") reported its financial results for the period ended December 31, 2023. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K (the "Report"). The information in this Item 2.02 and attached as Exhibit 99.1 to this Report will not be treated as "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. This information will not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or into another filing under the Exchange Act, unless that filing expressly incorporates this information by reference.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release issued by the Company on April 2, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PHIO PHARMACEUTICALS CORP. Date: April 2, 2024 By: /s/ Robert Bitterman Robert Bitterman President & Chief Executive Officer 3